Document is current
Any future updates will be listed below
-
Authors
Slurink, Isabel A. L. https://orcid.org/0000-0002-3310-0329
de Boer, Annemarijn R. https://orcid.org/0000-0003-4200-0917
Bonten, Marc J. M. https://orcid.org/0000-0002-9095-9201
Sturkenboom, Miriam C. J. M. https://orcid.org/0000-0003-1360-2388
Bruijning-Verhagen, Patricia C. J. L. https://orcid.org/0000-0003-4105-9669
-
Funding
Funding for this research was provided by:
ZonMw (10430252220010)
- License Information
-
More Information
Article History
Received: 23 December 2024
Accepted: 29 October 2025
First Online: 24 January 2026
Declarations
:
: MB has regular interaction with pharmaceutical and other industrial partners. He has not received personal fees or other personal benefits. UMCU and/or Ecraid received funding for study collaboration from AstraZeneca, Sanofi, Janssen, Pfizer, MSD, Novavax, Sequiris and GSK. UMCU and/or Ecraid received funding as part of the public private partnership IMI-funded COMBACTE-NET, COMBACTE-CARE, COMBACTE-MAGNET, VITAL and PriMaVeRA. MS is head of a department that conducts studies for the European Medicines Agency, the European Commission, and medicine manufacturers, all according to the ENCePP code of conduct. MS does not hold personal financial relationships with the companies. All other authors declare no competing interests.
